Asset Details
Do you wish to reserve the book?
Mechanism of sensitivity to cisplatin, docetaxel, and 5‐fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mechanism of sensitivity to cisplatin, docetaxel, and 5‐fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression
Do you wish to request the book?
Mechanism of sensitivity to cisplatin, docetaxel, and 5‐fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mechanism of sensitivity to cisplatin, docetaxel, and 5‐fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression
2022
Overview
The aim of this study was to: (a) explore the potential mechanism of cancer cell sensitivity to cisplatin, docetaxel, and 5‐fluorouracil (TPF) in oral squamous cell carcinoma (OSCC) patients overexpressing growth differentiation factor 15 (GDF15); and (b) identify potential alternative agents for patients who might not benefit from inductive TPF chemotherapy. The results indicated that OSCC cells overexpressing GDF15 were sensitive to TPF through a caspase‐9‐dependent pathway both in vitro and in vivo. Immunoprecipitation combined with mass spectrometry revealed that the erbB2 protein was a potential GDF15‐binding protein, which was verified by coimmunoprecipitation. Growth differentiation factor 15 overexpression promoted OSCC cell proliferation through erbB2 phosphorylation, as well as downstream AKT and Erk signaling pathways. When GDF15 expression was blocked, the phosphorylation of both the erbB2 and AKT/Erk pathways was downregulated. When OSCC cells with GDF15 overexpression were treated with the erbB2 phosphorylation inhibitor, CI‐1033, cell proliferation and xenograft growth colony formation were significantly blocked (P < .05). Thus, GDF15‐overexpressing OSCC tumors are sensitive to TPF chemoagents through caspase‐9‐dependent pathways. Growth differentiation factor 15 overexpression promotes OSCC proliferation through erbB2 phosphorylation. Thus, ErbB2 inhibitors could represent potential targeted drugs or an alternative therapy for OSCC patients with GDF15 overexpression. Growth differentiation factor 15 (GDF15)‐overexpressing oral squamous cell carcinoma (OSCC) tumors are sensitive to cisplatin, docetaxel, and 5‐fluorouracil chemoagents through caspase‐9‐dependent pathways. GDF15 overexpression promotes OSCC proliferation through erbB2 phosphorylation. Thus, erbB2 inhibitors could represent potential targeted drugs or an alternative therapy for OSCC patients with GDF15 overexpression.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Animals
/ Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Caspase
/ Cell Proliferation - drug effects
/ Cell Transformation, Neoplastic - drug effects
/ Drugs
/ ErbB2
/ GDF15
/ Growth Differentiation Factor 15 - metabolism
/ Humans
/ Kinases
/ Mice
/ Mouth Neoplasms - metabolism
/ Oral squamous cell carcinoma
/ Original
/ Phosphorylation - drug effects
/ Proteins
/ Receptor, ErbB-2 - antagonists & inhibitors
/ Receptor, ErbB-2 - metabolism
/ Signal Transduction - drug effects
/ Squamous Cell Carcinoma of Head and Neck - metabolism
/ Tumors
